Intercepting Cancer with the NFL and Cancer Treatment Centers of America

The Cancer Treatment Centers of America was founded in 1988. The group is dedicated to finding cures for every type of cancer possible/ The group also helps people struggling with anxiety and depression as well. Cancer Treatment Centers of America has five main offices located in the United States to help those diagnosed any type of cancer.

The five offices in the United States are located in the following areas. The offices are in Zion, Illinois, Goodyear, Arizona, Newman, Georgia, Philadelphia, Pennsylvania, and Tulsa, Oklahoma. The main headquarters of the group is located in Boca Raton, Florida. The group along with the NFL Alumni Association have come together to create a program in order to get the word out about prostate cancer screening. The event runs from September first until October fifteenth of this year.

The goal of the program is simple and begins with a Prostate Pep talk. NFL coaches like Dick Vermeil, Bill Cowher, and Herm Edwards have done a series of public service announcements stressing the importance of prostate cancer screenings for men.

The goal is to get men that are forty years of age and older to sign up for a prostate screening. If the man meets certain requirements and is one of the first two thousand men to sign up for the screening the exam is totally free for that man. Cancer Treatment Centers of America is also teaming up with LabCorp to provide free screenings. If the individual is after the two thousand mark then the screening will only cost twenty-five dollars.

This event is crucial for spreading the word about the importance of men being screened for prostate cancer. Getting screened early is key to helping men live long and happy life. That should be worth it for any man.

Visit More : www.didyouknow.it/treatment/cancer-treatment-centers-america-provides-hope-ovarian-cancer-patients/

Dr. David Samadi:

Dr. David Samadi is a well known Physician that specializes in Oncology. Dr. Samadi has performed many successful prostate surgeries using a special Robotic surgical method. Currently, Dr. Samadi is Chief of Surgery at the Lennox Hill Hospital located in Manhattan New York. Dr. David Samadi has also performed many successful surgeries involving Cancer of the bladder. Dr. Samadi is a Physician that is in demand due to his special surgical techniques as well as his knowledge of certain Cancers.

Dr. Samadi is able to diagnose as well as properly treat Cancer. Dr. Samadi believes that early detection is key to a successful recovery as well as cure. In addition, the doctor does employ surgery as part of a treatment plan followed by Cancer treatment if necessary. Dr. Samadi also treats Kidney Cancers as well as Pelvic Inflammatory diseases.

Dr. Samadi uses Laparoscopic Radical Prostatectomy which is considered an non invasive procedure. This procedure has produced exceptional results when used to treat Prostate and Kidney Cancers. Non-invasive procedures speed recovery time, leave less scarring and patients experience little to no pain following a procedure such as this, and learn more about Dr. David Samadi.

Dr. David Samadi earned his medical degree from the Stoney Brook School of Medicine. In addition, following his graduation from Stoney Brook Dr. Samadi had additional medical training at Montefiore Medical Center. His additional training at Montefiore enabled Dr. Samadi to specialize in diseases of the Prostate and the Kidneys.

Previously, Dr. Samadi was on staff at Columbia Presbyterian Hospital. In addition, Dr. Samadi was on staff for a period of five years at the Mount Sinai School of Medicine. Through his hard work and exceptional devotion to his profession, Dr. Samadi quickly became the Head of Robotic Surgery. The doctor earned a reputation for being one of the most experienced as well as one of the best surgeons within the New York Metro area. By the mid 2000’s Dr. Samadi was said to be one of the highest paid Physician’s within the nation, and more information click here.

Dr. Samadi has appeared on several Television shows such as Fox and Friends. One segment of Fox & Friends focused on the issue of women having to pay higher insurance rates in comparison to men. Dr. Samadi expressed his concern about the issue and he also gave insight on how to make insurance affordable for everyone, and Twitter.com.

Dr. Samadi also conducts speaking engagements. In addition, he has returned to his former medical college numerous times to address the graduating class. Dr. Samadi plans to continue to return to Stoney Brook as long as he is able to do so.

Dr. Samadi has had a successful career as a surgeon. He continues to gain notoriety for his exceptional work and knowledge of common Cancers. Dr. Samadi continues to research various ways to improve Cancer treatment in the future.

Oncotarget Writes For Scientific Researchers

The most recent, as well as the archived, information and scientific research results can be found in the Oncotarget publications. Oncotarget publishes papers relating to scientific results as quickly as they are released by researchers. The company wants to guarantee that the public gets the much awaited results as soon as they become available. This is a company for which peer reviews are written for various papers. They will accept the papers to help the writer with their research, and to get it published so that the findings can be shown in a timely manner. They publish results for medical and scientific research on a variety of topics. Oncotarget publishes papers from a wide range of topics. They publish research findings in Neuroscience, Pharmacology, Endocrinology, Cell Biology, Metabolism, Cardiology, and many other topics. The company allows scientific researchers put forth their best effort in order to enable people to one day have a life without any diseases. The journal publishing company was founded in 2011.

It publishes new copies every week, and has made an impact due to their work, and their reviews to show scientific research results as quickly as they are received. They had the highest ranking possible in 2015. They were number one in Total Documents, which meant that they were above other journals that were written on the subject of Oncology.The journals published by Oncotarget are online publications, but they will print them according to the demand for hard copies. Their want to make sure that the community gets the results and findings of scientific and medical research as quickly as can be provided. The name Oncotarget was derived from a combination of the names of various diseases, which also include the many pathways found in aging, cancer, and other diseases.

In 2016, the publisher was ranked among the top 50 oncology journals. This rating was done by SCImago Journal and Country Rank. Although the journal covers many topics as of now, it was once only written about Oncology. Oncotarget was instrumental in getting Impact to include other sections for various other topics.The two editors in chief of the journal, Andrei V. Gudkov and Mikhail V. Blagosklonny, are both doctors. They are currently at the Roswell Park Cancer Institute in Buffalo, New York. With numerous affiliations to their credit, their focus is on various aspects of cancer treatment. The Editors at Oncotarget are bound by a code of conduct, and code of best practice guidelines for editors and publishers. The manuscripts received by the editors are evaluated according to scientific quality and merit. Any writing that is not published remains confidential, and is not for any one’s private use.

Oncotarget: A Scion of Open Access Peer-reviewed Journalism

Since its founding in 2010. Oncotarget has carved out a name for itself as one of the leading peer-reviewed journals globally. Its Impact Factor (IF) as measured by Thomson Reuters JCR has risen from 4.784 in 2011 to 5.168 in the 2016/2017 grading year. Between 2011 and 2016, Oncotarget’s citations have increased over 20 times from 493 to 10,452. The journal’s five-year Impact Factor stands at 5.415 as of 2015/2016 ratings. It has been given the highest ranking, Q1, by Scopus/SJR for its excellent contributions in medicine and oncology. This growing popularity informed the journal’s decision to expand the fields to be covered by the articles to be included in its publications. The fields have expanded from oncology to other fields including cell biology, pharmacology, neuroscience and cardiology. It also accepts papers on metabolism and endocrinology among other fields. Learn more about Oncotarget at Research Gate.

Journal Profile: Success Factors

Oncotarget is published weekly by Impact Journals in English. The medicine journal is peer reviewed by its highly experienced editorial board members and editors. The over a hundred editors and editorial board members are specialists in a wide range of fields including pathology, oncology, aging, immunology and microbiology, and cell biology. Some of them such as Andrew Schally are excellent research scientists who have been honored with the prestigious Nobel Prize. The excellent service delivery by the journal’s editorial board was recognized in 2013 when four members were honored with the Breakthrough Prize. These individuals have brought their experience and expertise to Oncotarget and helped the journal build a strong reputation rapidly. Others such as Mikhail Blagosklonny and Andrei V. Gudkov, who are the founding editors-in-chief, are experienced research scientists who have led cancer research for many years.

As an open access, Oncotarget accepts articles from authors around the world. It is an indication of its commitment towards knowledge and information dissemination with the view of meeting the ultimate goal of a world free from diseases. Its free access policy has also driven its popularity especially within scientific communities. Moreover, the journal’s success can also be attributed to its multidisciplinary nature. Covering numerous disciplines ensures that the journal’s impact factor and citations increase significantly. Check Oncotarget journal at scimagojr.com

Seattle Genetics Set to Raise Large Funds

Seattle Genetics, a company that works towards producing cancer medicines, has started their largest round of financing. This biotech company is increasing its 480 million public stock offering to 552 million through the interest from investors. This round of funding will go towards increasing their drug pipeline, expanding their cancer research, and continuing to grow the company.

Clay Siegall, CEO of Seattle Genetics, expects to hire about 100 people over the next five years. This hiring will increase the employees to 1,300. During this expansion, Seattle Genetics is looking to find other properties to accommodate their growth.

Seattle Genetic, which was founded in 1998, is has been around longer than any company. The company is not yet profitable, of the 77 million in revenue 47.5 million was lost. Siegall is not concerned about this loss because he says that they will continue with the plans to grow. It is not uncommon for Biotech companies to not turn a profit. It may take a while for them to turn a profit, even years.

Seattle Genetics is a biotech company that is geared towards medical research for cancer patients. Their focus is on antibody based therapies for the treatment of cancer. These type of treatments are less harsh than standard chemotherapy. They are dedicated to the advancement of cancer and other hard to treat diseases. They value helping patients, teamwork, and scientific excellence. Clay Siegall co-founded it in 1998 and is now the CEO and Chairman of the Board. He has guided his company through leadership of creating ADCETRIS, the leading anti-body treatment drug.

Seattle Genetics and Their CEO Clay Siegal

Seattle Genetics and Their CEO Clay Siegal
The biotechnological company, Seattle Genetics, was founded in 1998 on the premises of innovative scientific research. The founder, Clay Siegal, is a trained scientist himself, and he has a passion for developing new medicines and treatments for patients all around the world. In truth, the Seattle Genetics company is an extension of its founder and CEO in policy and practice.
Seattle Genetics
The study of human illnesses and disease is what Seattle Genetics specializes in, specifically with a focus on cancer. Their research is to find a cancer therapy that will be both effective and efficient. That is to say, their goal is to develop a fully utilizable drug therapy that will only target the cancerous cells in the body and destroy them. Current practices, like chemotherapy, lacks the efficiency due to the fact that they can also harm non-cancerous cells.
Moreover, the scientists and doctors that assist in the research are fully committed to providing the best experience for their patients. One of the company’s values is to have a ‘passion for helping patients.’ A part of this is finding a way to put the patient through a drug therapy that won’t have harmful side effects to their body.
Clay Siegal
The CEO and Founder of the Seattle Genetics company, Clay Siegal, has the same passion for his patients and the research. After receiving his PhD in Genetics from George Washington University, Dr. Siegal went on to work for both the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. He took both his experience and his education into the founding of Seattle Genetics.
Having already helped develop a new alternative drug therapy for cancer patients, Dr. Siegall and his company Seattle Genetics are looking further into areas that have unmet medical needs. This means that the passionate team at Seattle Genetics, and their CEO, can bring their passion and scientific integrity into unexplored genetic areas to develop treatments to both better science and improve mankind’s life expectancy!

Read More:

https://www.glassdoor.com/Reviews/Seattle-Genetics-Reviews-E12902.htm